Clinical Trials Browser

Phase 3 × Has announcements × Classical hematology × Clear all

NCT02048813 2025-11-28

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 3 Active not recruiting

529 enrolled 12 charts 2 FDA

Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01583218 2023-08-07

APEX

Phase 3 Completed

7,513 enrolled 18 charts 1 FDA

Classical hematology

Venous Thromboembolism

NCT03036813 2023-07-27

GBT_HOPE

Phase 3 Completed

449 enrolled 17 charts 1 FDA

Classical hematology

Anemia, Sickle Cell

NCT03020160 2023-01-11

HAVEN 4

Phase 3 Completed

48 enrolled 44 charts 1 FDA

Classical hematology

Hemophilia A

NCT02847637 2022-11-16

HAVEN 3

Phase 3 Completed

152 enrolled 46 charts 1 FDA

Classical hematology

Hemophilia A

NCT02631070 2021-12-17

MEDALIST

Phase 3 Completed

229 enrolled 36 charts 2 FDA

Classical hematologyMyeloid

Anemia, Myelodysplastic Syndromes

NCT02622321 2021-06-24

HAVEN 1

Phase 3 Completed

113 enrolled 45 charts 1 FDA

Classical hematology

Hemophilia A

NCT02795767 2021-06-02

HAVEN 2

Phase 3 Completed

88 enrolled 65 charts 1 FDA

Classical hematology

Hemophilia A

NCT01179217 2020-08-19

A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia

Phase 3 Completed

230 enrolled 19 charts 1 FDA

Classical hematology

Vaso-Occlusive Crises, Anemia, Sickle Cell

NCT02389621 2018-10-30

L-PLUS 2

Phase 3 Completed

215 enrolled 24 charts 1 FDA

Classical hematology

Thrombocytopenia

NCT01444417 2017-02-09

Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

Phase 3 Completed

62 enrolled 16 charts 1 FDA

Classical hematology

Purpura, Thrombocytopenic, Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic